文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

局部枸橼酸抗凝对接受持续肾脏替代治疗的急性肾损伤危重患者凝血酶生成、纤溶和血小板功能的影响:一项前瞻性研究

Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study.
PubMed 文献 · Ann Intensive Care · 2022-03-31
一句话结论危重AKI行CRRT患者处于高凝状态,局部枸橼酸抗凝不影响全身凝血酶生成、D-二聚体或血小板功能,全身凝血参数可反映回路内结果。

这项探索性前瞻性研究纳入11例在三级医院30床ICU接受局部枸橼酸抗凝(RCA)下持续肾脏替代治疗(CRRT)的急性肾损伤(AKI)危重成人患者,排除已有血栓或出血倾向及CRRT不足48小时者。基线时全部患者因子VIII和血管性血友病因子浓度高于参考范围,凝血酶生成峰值显著增高。CRRT期间全身最大凝血酶生成峰值、达峰时间、纤维蛋白原、D-二聚体和血小板功能分析均无显著变化。患者动脉管路与回路配对血样之间无显著差异。

要点

  • 基线时全部11例患者因子VIII和血管性血友病因子浓度高于参考范围,凝血酶生成峰值显著增高,提示危重AKI行CRRT患者处于高凝状态。
  • CRRT期间全身最大凝血酶生成峰值、达峰时间、纤维蛋白原、D-二聚体和血小板功能分析均无显著变化。
  • 患者动脉管路与回路配对血样之间凝血参数无显著差异,全身凝血参数可反映回路内结果。
  • 局部枸橼酸抗凝不影响凝血酶生成、D-二聚体或血小板功能。

适用人群与场景

  • 入住三级医院30床ICU、因急性肾损伤(AKI)需要接受局部枸橼酸抗凝(RCA)下持续肾脏替代治疗(CRRT)的危重成人患者。
  • 排除已有血栓倾向、出血倾向或CRRT持续时间不足48小时的患者。

研究设计与关键结果

  • 探索性前瞻性研究纳入11例患者(平均年龄62.4岁,82%男性),基线时全部患者因子VIII和血管性血友病因子浓度高于参考范围,凝血酶生成峰值显著增高。
  • CRRT期间全身最大凝血酶生成峰值、达峰时间、纤维蛋白原、D-二聚体和血小板功能分析均无显著变化。
  • 患者动脉管路与回路配对血样之间凝血参数无显著差异。

证据类型、等级与局限

  • 证据类型:探索性前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Regional citrate anticoagulation (RCA) is recommended for continuous renal replacement therapy (CRRT). However, filter life varies and premature filter clotting can occur. The aims of this explorative prospective study were to investigate the effects of RCA on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving CRRT, to compare clotting parameters between systemic and intra-circuit blood samples, and to screen participants for coagulation disorders. We recruited critically ill adult patients admitted to a 30-bedded Intensive care unit in a tertiary care hospital who required CRRT with RCA for acute kidney injury (AKI). Patients with pre-existing thrombotic, bleeding tendencies or a CRRT duration less than 48 h were excluded. We measured coagulation and thrombophilia parameters at baseline. Thrombin generation, D-dimer and platelet function were measured pre-CRRT and at 12, 24, 36, 48 and 72 h after commencing CRRT using blood samples taken from the arterial line and the circuit.

RESULTS: At baseline, all eleven patients (mean age 62.4 years, 82% male) had Factor VIII and von Willebrand Factor concentrations above reference range and significantly increased peak thrombin generation. During CRRT, there were no significant changes in systemic maximum peak thrombin generation, time to peak thrombin generation, fibrinogen, D-dimer and platelet function analysis. We observed no significant difference between paired samples taken from the patient's arterial line and the circuit.

CONCLUSIONS: Critically ill patients with AKI requiring CRRT are hypercoagulable. Citrate used for anticoagulation during CRRT does not affect thrombin generation, D-dimer or platelet function. Systemic clotting parameters reflect intra-circuit results.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02486614. Registered 01 July 2015-Registered after recruitment of first patient. https://clinicaltrials.gov/ct2/show/NCT02486614.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Fisher R, Moore GW, Mitchell MJ, et al. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Ann Intensive Care. 2022. PMID: 35355147. doi:10.1186/s13613-022-01004-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。